Quantcast

MediSapiens to Provide Bioinformatics Application to Bayer HealthCare

May 13, 2014

HELSINKI, May 13, 2014 /PRNewswire/ –

MediSapiens Ltd, a Finnish company developing bioinformatics applications for the
pharmaceutical industry, today announced that it will provide Bayer HealthCare with a new
software solution for analysis and visualization of genomics data. This software system,
called the Integrated Genomics Platform, will serve as a centralized access to genomics
data used throughout a research organization. The Integrated Genomics Platform provides
storage and access to a vast collection of clinical genomics data, coupled with an
extensive set of tools for analysis and visualization of the data.

“Data alone serves very little purpose. Without structure and proper means of
interpretation, it is merely numbers. And when we talk about genomics data, the sheer
amount of it is almost terrifying. The Integrated Genomics Platform will turn the vast
pool of genomics data into knowledge that can be used to drive decision-making processes
in pharmaceutical research and development,” says Sami Kilpinen, CEO of MediSapiens.

About MediSapiens

MediSapiens is a bioinformatics company developing inspiring web applications for
genomics researchers, the pharmaceutical industry and personalized medicine. MediSapiens
has unique know-how in developing software solutions for integration of both molecular and
clinical data from preclinical models to interpreting comprehensive molecular profiles of
individual cancer patients in clinical settings. Based on the world’s largest unified gene
expression database, MediSapiens’ platform extends into highly tailored solutions to meet
the exact needs of various demanding research environments.

For more information visit http://www.medisapiens.com or email
contact@medisapiens.com

        Media Contact:
        Sami Kilpinen, CEO, Co-Founder
        MediSapiens Ltd
        Erottajankatu 19B
        00130 Helsinki
        Finland
        sami.kilpinen@medisapiens.com

SOURCE MediSapiens Ltd


Source: PR Newswire



comments powered by Disqus